Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Mantle-Cell Lymphoma Clinical Trial

Official title:

A Phase II Study Evaluating Combined Zevalin(Ibritumomab Tiuxetan)and Velcade(Bortezomib)in Relapsed/Refractory Mantle Cell Lymphoma

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT01497275
• Other study ID #: Pro00032517
• Status: Terminated
• Phase: Phase 2
• First received: December 20, 2011
• Last updated: June 18, 2015
• Start date: February 2012
• Est. completion date: May 2014

Study information

• Verified date: June 2015
• Source: Duke University
• Contact: n/a
• Is FDA regulated: No
• Health authority: United States: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effects (good and bad) of the combination of ibritumomab tiuxetan (Zevalin) and bortezomib (Velcade) in patients with relapsed/refractory mantle cell lymphoma.

Zevalin is a monoclonal antibody that is combined with a radioactive substance and given with another monoclonal antibody called rituximab (Rituxan). It works by attaching to cancer cells and releasing radiation to damage those cells. Both Zevalin and Rituxan are given in this study, along with Velcade.

Description:

This is a non-randomized, unblinded single arm Phase II trial to evaluate the combination of yttrium90 ibritumomab tiuxetan and bortezomib in patients with relapsed/refractory mantle cell lymphoma (MCL). Standard hematology and chemistries, imaging and bone marrow biopsies will be done.

Research tests: 17cc of blood will be collected at screen, Day 8 OR 11 and month 3. Samples will be collected and stored for future analysis. These analyses may include but are not limited to measurements of proteasome inhibition. No genetic studies will be performed on these samples. Samples will be destroyed at the end of the study.

Primary Objective Estimate the overall response rate (CR + PR) of the combination of bortezomib and ibritumomab tiuxetan in patients with relapsed/refractory mantle cell lymphoma.

Secondary Objectives

• Estimate the progression free and overall survival in patients with relapsed/refractory mantle cell lymphoma who receive bortezomib and ibritumomab tiuxetan.

• Assess the toxicity of the combination of bortezomib and ibritumomab tiuxetan in patients with relapsed/refractory MCL.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 5
• Est. completion date: May 2014
• Est. primary completion date: May 2014
• Accepts healthy volunteers: No
• Gender: Both
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Patients with relapsed or refractory Mantle Cell lymphoma with measurable disease.

• Age > 18 years old

• Expected survival >/= 3 months

• Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 at initiation of study (Appendix I).

• Laboratory tests meet the levels specified in the protocol

Exclusion Criteria:

• Patients must not have received chemotherapy, radiation or surgical resection of malignancy within 3 weeks of study initiation. However, if they have received nitrosurea or mitomycin C then they should not be enrolled in the study until 6 weeks after therapy was last received.

• No limitations to number of prior therapies

• No prior radioimmunotherapy (RIT)

• Prior bortezomib is allowed

• Patient must be fully recovered from all toxicities associated with prior surgery, radiation treatment, chemotherapy or immunotherapy.

• No active, serious infection or medical or psychiatric illness likely to interfere with participation in this clinic trial

• No known HIV infection

• No active central nervous system (CNS) involvement

• Bone Marrow Involvement >/= 25% within 30 days of initiation of study treatment

• Pregnant or breast feeding

• No patients who have received Granulocyte colony-stimulating factor (G-CSF) or Granulocyte macrophage colony-stimulating factor (GM-CSF) within the 14 days prior to initiating protocol

• No patient who has had major surgery within the four weeks prior to initiating protocol therapy

• No patients with pleural effusion or significant ascites

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Lymphoma
• Lymphoma, Mantle-Cell
• Mantle-Cell Lymphoma

Intervention

Drug:
• Rituximab, Bortezomib,Y90 ibritumomab tiuxetan
Rituximab 250mg/m2 will be given on day 1 and on day 8. Bortezomib 1.5mg/m2 will be given on Days 1, 4, 8, and 11. Y90 ibritumomab tiuxetan will be given on Day 8. Dosage will be based on the platelet count obtained at the time of study enrollment. The dose will be 0.4mCi/kg unless the enrollee's platelets are between 100,000 and 150,000 in which case a dose of 0.3mCi/Kg will be used. Patients who weigh over 80 Kg will receive a maximum dose of 32mCi.

Locations

Country	Name	City	State
United States	Duke University Medical Center	Durham	North Carolina

Sponsors (2)

Lead Sponsor	Collaborator
Duke University	Spectrum Pharmaceuticals, Inc

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Response Rate (Complete Response + Partial Response)	Disease will be assessed every 3 months.; The Cheson criteria will be used to define response: Complete Response = Complete disappearance of all detectable clinical and radiographic evidence of disease and disappearance of all disease-related symptoms if present prior to therapy.; Partial Response = A decrease of = 50% in the sum of the products of their greatest transverse diameters (SPD) of up to six of the largest dominant nodes or nodal masses. These nodes or masses should be selected according to the following features: a) they should be clearly measurable in at least two perpendicular measurements; b) they should be from as disparate regions of the body as possible; and c) they should include mediastinal and retroperitoneal areas of disease whenever these sites are involved.	3 months	No
Secondary	Number of Participants With Progression Free Survival	Progression-free survival will be defined as time from on-study to disease progression or death, whichever comes first	6 months	No
Secondary	Overall Survival at 1 Year	Number of participants who were alive at the 1 year time point. (Overall survival will be defined as the time from on-study to death due to any cause.)	1 year	No
Secondary	Overall Survival at 5 Year	Number of participants who were alive at the 5 year time point. (Overall survival will be defined as the time from on-study to death due to any cause.)	5 year	No